TRACON Pharmaceuticals Stock Forecast, Price & News

TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

Is TRACON Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRACON Pharmaceuticals stock.
View analyst ratings for TRACON Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than TRACON Pharmaceuticals?

Wall Street analysts have given TRACON Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TRACON Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for TRACON Pharmaceuticals.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) posted its quarterly earnings data on Wednesday, August, 11th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.24.
View TRACON Pharmaceuticals' earnings history.

How has TRACON Pharmaceuticals' stock price been impacted by Coronavirus?

TRACON Pharmaceuticals' stock was trading at $1.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TCON shares have increased by 202.8% and is now trading at $4.27.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TCON?

5 equities research analysts have issued 12-month target prices for TRACON Pharmaceuticals' shares. Their forecasts range from $12.00 to $24.00. On average, they anticipate TRACON Pharmaceuticals' stock price to reach $15.75 in the next year. This suggests a possible upside of 268.9% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the following people:

• Charles P. Theuer, President, Chief Executive Officer & Director
• Scott B. Brown, Chief Financial Officer
• Bonne J. Adams, Senior Vice President-Clinical Operations
• James L. Freddo, Chief Medical Officer
• Mark C. Wiggins, Chief Business Officer

Who are some of TRACON Pharmaceuticals' key competitors?

Some companies that are related to TRACON Pharmaceuticals include TCR2 Therapeutics (TCRR), Opthea (OPT), Oyster Point Pharma (OYST), Orchard Therapeutics (ORTX), Cabaletta Bio (CABA), Solid Biosciences (SLDB), Cardiff Oncology (CRDF), Candel Therapeutics (CADL), Achilles Therapeutics (ACHL), AVROBIO (AVRO), Harpoon Therapeutics (HARP), Fennec Pharmaceuticals (FENC), Gamida Cell (GMDA), Eiger BioPharmaceuticals (EIGR) and Aptose Biosciences (APTO).
View all of TCON's competitors.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.44%), BlackRock Inc. (1.90%), Renaissance Technologies LLC (1.12%), Geode Capital Management LLC (0.89%), State Street Corp (0.38%) and Dimensional Fund Advisors LP (0.37%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends for TRACON Pharmaceuticals.

Which major investors are selling TRACON Pharmaceuticals stock?

TCON stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace LLP, Renaissance Technologies LLC, BlackRock Inc., Susquehanna International Group LLP, Morgan Stanley, Morgan Stanley, and Citadel Advisors LLC.
View insider buying and selling activity for TRACON Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying TRACON Pharmaceuticals stock?

TCON stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, Telemetry Investments L.L.C., Geode Capital Management LLC, Northern Trust Corp, GSA Capital Partners LLP, JPMorgan Chase & Co., and Wells Fargo & Company MN. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier, and Scott B Brown.
View insider buying and selling activity for TRACON Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $4.27.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals has a market capitalization of $82.97 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-16,770,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

How many employees does TRACON Pharmaceuticals have?

TRACON Pharmaceuticals employs 18 workers across the globe.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

Where are TRACON Pharmaceuticals' headquarters?

TRACON Pharmaceuticals is headquartered at 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at (858) 550-0780 or via email at [email protected].